Showing results (121-130 of 221) with videos related to

Sort By:
Pageof 23
Journal of the European Academy of Dermatology and Venereology : JEADV|January 8, 2014
Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trialC Paul, K Reich, A B Gottlieb, et al.
Pediatric Research|July 31, 2001
Impaired glucocorticoid synthesis in premature infants developing chronic lung diseaseK L Watterberg, J S Gerdes, K L Cook
The British Journal of Dermatology|August 4, 2019
A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatmentK Reich, M Augustin, D Thaçi, et al.
The British Journal of Dermatology|October 28, 2018
Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trialK Reich, J Sullivan, P Arenberger, et al.
The British Journal of Dermatology|May 9, 2012
Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label studyC Leonardi, J M Sobell, J J Crowley, et al.
The Journal of Dermatological Treatment|June 11, 2019
Adiponectin levels in a large pooled plaque psoriasis study populationS Gerdes, A Pinter, M Biermann, et al.
The Journal of Pediatrics|December 8, 1998
Regional hemodynamic effects of dopamine in the sick preterm neonateI Seri, S Abbasi, D C Wood, et al.
Journal of Perinatology : Official Journal of the California Perinatal Association|May 29, 2002
Regional hemodynamic effects of dopamine in the indomethacin-treated preterm infantIstvan Seri, Soraya Abbasi, Dennis C Wood, et al.
The Journal of Investigative Dermatology|March 12, 2002
Dimethylfumarate inhibits tumor-necrosis-factor-induced CD62E expression in an NF-kappa B-dependent mannerR Loewe, M Pillinger, R de Martin, et al.
The British Journal of Dermatology|June 2, 2020
Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE studyK Reich, J Sullivan, P Arenberger, et al.
Pageof 23